secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001664710-24-000088
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Q3 net loss $53M; cash $530.7M; Phase 2 PAH trial fully enrolled
----------------------------------------------------------------------

- Net loss of $53.0M in Q3 2024 vs $39.4M in Q3 2023; R&D expenses rose to $49.2M.
- Cash and cash equivalents $530.7M as of Sep 30, 2024; ATM proceeds extend runway into Q3 2027.
- Completed enrollment ahead of schedule in Phase 2 TROPOS trial (cibotercept) for pulmonary arterial hypertension.
- Appointed Yung H. Chyung, M.D. as Chief Medical Officer effective Nov 1, 2024.
- Expects clinical data updates from three assets over next nine months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000088/0001664710-24-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000088/kros-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer